The efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer
| Autor: | Ting Wang, Dan-Ni Zhou, Wanli Deng, Hua Sui, Linguangjin Wu, Jun-Zhi Ma |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Lung Neoplasms Adolescent medicine.medical_treatment Programmed Cell Death 1 Receptor Antineoplastic Agents Subgroup analysis Cochrane Library B7-H1 Antigen law.invention Young Adult 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Carcinoma Non-Small-Cell Lung Internal medicine medicine Humans 030212 general & internal medicine Lung cancer Immune Checkpoint Inhibitors Proportional Hazards Models Randomized Controlled Trials as Topic Chemotherapy business.industry Incidence (epidemiology) Hazard ratio General Medicine Middle Aged medicine.disease Progression-Free Survival Treatment Outcome 030220 oncology & carcinogenesis Meta-analysis Female business |
| Zdroj: | Medicine. 100:e25145 |
| ISSN: | 1536-5964 0025-7974 |
| DOI: | 10.1097/md.0000000000025145 |
| Popis: | BACKGROUND Immune checkpoint inhibitor therapy for non-small cell lung cancer is widely used in clinical practice. However, there has not been a systematic statistical proof of the efficacy of PD-1 inhibitors in patients with advanced cancer. This meta-analysis aims to evaluate its efficacy and related influencing factors, so as to provide a basis for clinical diagnosis and treatment. OBJECTIVE To assess the effectiveness and safety of programmed death-1 (PD-1)/PD ligand 1 (PD-L1) inhibitors versus chemotherapy as second-line or late-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) via a systematic review of published randomized controlled trials (RCTs). METHODS Studies were identified through PubMed, EMBASE, and Cochrane Library electronic databases. RevMan 5.3.5 was used to analyze the data extracted from all eligible studies. RESULTS All 4122 eligible patients from 8 RCTs were included in this study. The meta-analysis showed that PD-1/PD-L1 inhibitors could significantly improve overall survival (hazards ratio [HR] 0.71, 95% confidence interval [CI] 0.66-0.77, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|